Akari Therapeutics (AKTX) Interest Expenses (2011 - 2026)
Akari Therapeutics (AKTX) reported Interest Expenses of $100000.0 for Q1 2026, little changed on a YoY basis from $100000.0 in Q1 2025, and up 10100.0% sequentially from -$1000.0 in Q4 2025.
Akari Therapeutics (AKTX) Interest Expenses (2011 - 2026) Analysis & Trends
Akari Therapeutics (AKTX) has 11 years of Interest Expenses data on file, last reported at $100000.0 in Q1 2026.
- For the quarter ending Q1 2026, Interest Expenses changed 0.0% year-over-year to $100000.0; the trailing twelve-month figure through Mar 2026 stood at $195000.0 (up 30.87% YoY), and the FY2025 full-year result was $63.4 million, up 63256.0% from the prior year.
- Interest Expenses rose to $100000.0 in Q1 2026, from -$1000.0 in the prior quarter.
- In the past five years, Interest Expenses ranged from a high of $34.6 million in Q4 2022 to a low of -$20000.0 in Q4 2024.
- A 5-year average of $3.9 million and a median of $69000.0 in 2024 frame the typical range for Interest Expenses.
- Across the five-year window, Interest Expenses slumped 211.11% in 2024 and jumped 95.0% in 2025, its largest moves.
- Tracing AKTX's Interest Expenses over 5 years: stood at $34.6 million in 2022, then tumbled by 99.95% to $18000.0 in 2023, then tumbled by 211.11% to -$20000.0 in 2024, then jumped by 95.0% to -$1000.0 in 2025, then jumped by 10100.0% to $100000.0 in 2026.
- Business Quant data shows AKTX's Interest Expenses at $100000.0 in Q1 2026, -$1000.0 in Q4 2025, and -$4000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | -42,141.15 |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | 100,000.00 |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 32.89 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 420.30 Mn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 28.30 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | 1.17 Bn |
| 10 | Alnylam Pharmaceuticals | 36.08 Bn | 33.07 Bn | 959.66 Mn | 69.29 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 100,000.00 |
| Mar 31, 2026 | 100,000.00 |
| Dec 31, 2025 | -1,000.00 |
| Dec 31, 2025 | -1,000.00 |
| Sep 30, 2025 | -4,000.00 |
| Sep 30, 2025 | -4,000.00 |
| Jun 30, 2025 | 100,000.00 |
| Jun 30, 2025 | 100,000.00 |
| Mar 31, 2025 | 100,000.00 |
| Mar 31, 2025 | 100,000.00 |
| Dec 31, 2024 | -20,000.00 |
| Dec 31, 2024 | -20,000.00 |
| Sep 30, 2024 | 69,000.00 |
| Sep 30, 2024 | 69,000.00 |
| Dec 31, 2023 | 18,000.00 |
| Dec 31, 2023 | 18,000.00 |
| Dec 31, 2022 | 34.62 Mn |
| Dec 31, 2022 | 34.62 Mn |
| Dec 31, 2021 | 30.32 Mn |
| Dec 31, 2021 | 30.32 Mn |